Filing Details
- Accession Number:
- 0001209191-17-006404
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-01-31 16:49:32
- Reporting Period:
- 2017-01-31
- Filing Date:
- 2017-01-31
- Accepted Time:
- 2017-01-31 16:49:32
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1370053 | Anaptysbio Inc | ANAB | Pharmaceutical Preparations (2834) | 203828755 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1639935 | Nicholas Lydon | C/O Anaptysbio, Inc. 10421 Pacific Center Court, Suite 200 San Diego CA 92121 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-01-31 | 203,625 | $0.00 | 270,957 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2017-01-31 | 16,666 | $15.00 | 287,623 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series B Preferred Stock | Disposition | 2017-01-31 | 80,877 | $0.00 | 80,877 | $0.00 |
| Common Stock | Series C Preferred Stock | Disposition | 2017-01-31 | 55,403 | $0.00 | 55,403 | $0.00 |
| Common Stock | Series D Preferred Stock | Disposition | 2017-01-31 | 67,345 | $0.00 | 67,345 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct |
Footnotes
- In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.
Billionaire Hedge Funds
